Viatris Stock Shows Every Sign Of Being Modestly Undervalued
- By GF Value
The stock of Viatris (NAS:VTRS, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $13.745 per share and the market cap of $16.6 billion, Viatris stock is estimated to be modestly undervalued. GF Value for Viatris is shown in the chart below.
Because Viatris is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth.
Link: These companies may deliever higher future returns at reduced risk.
It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. Viatris has a cash-to-debt ratio of 0.04, which is in the bottom 10% of the companies in Drug Manufacturers industry. The overall financial strength of Viatris is 3 out of 10, which indicates that the financial strength of Viatris is poor. This is the debt and cash of Viatris over the past years:
Investing in profitable companies carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a company with high profit margins offers better performance potential than a company with low profit margins. Viatris has been profitable 9 years over the past 10 years. During the past 12 months, the company had revenues of $11.9 billion and loss of $1.11 a share. Its operating margin of -0.86% in the middle range of the companies in Drug Manufacturers industry. Overall, GuruFocus ranks Viatris's profitability as fair. This is the revenue and net income of Viatris over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Viatris is -3.6%, which ranks worse than 76% of the companies in Drug Manufacturers industry. The 3-year average EBITDA growth rate is -18.1%, which ranks worse than 81% of the companies in Drug Manufacturers industry.
Another method of determining the profitability of a company is to compare its return on invested capital to the weighted average cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. When the ROIC is higher than the WACC, it implies the company is creating value for shareholders. For the past 12 months, Viatris's return on invested capital is -0.28, and its cost of capital is 5.54. The historical ROIC vs WACC comparison of Viatris is shown below:
In closing, the stock of Viatris (NAS:VTRS, 30-year Financials) appears to be modestly undervalued. The company's financial condition is poor and its profitability is fair. Its growth ranks worse than 81% of the companies in Drug Manufacturers industry. To learn more about Viatris stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
This article first appeared on GuruFocus.
